Brief: PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints In First Line Recurrent/Metastatic HPV16-Positive Head, Neck Cancer
09/05/2024 22:54
May 9 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH VERSATILE-002 PHASE 2 CLINICAL TRIAL MEETS
PRIMARY
STUDY ENDPOINTS IN FIRST LINE RECURRENT/METASTATIC
HPV16-POSITIVE HEAD AND NECK CANCER
* PDS BIOTECHNOLOGY CORP: PLANS TO INITIATE A PIVOTAL
CLINICAL
TRIAL IN 2024 TO ADVANCE ITS LEAD PROGRAM IN ADVANCED HEAD AND
NECK SQUAMOUS CELL CANCERS
Source text for Eikon: ID:nGNX6CTsJR
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing